Merit Medical Systems, Inc. (MMSI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals solid financial performance with record-high gross margins, strong operating income growth, and positive revenue projections, especially in the cardiovascular and endoscopy segments. Despite some concerns over OEM revenue and cautious Q1 2026 guidance, the company's strategic acquisitions and optimistic long-term outlook for Rhapsody and other products support a positive sentiment. The market cap suggests a moderate reaction, leading to a 2%-8% stock price increase prediction.
Key Financial Performance
Total Revenue (Q4 2025) $393.9 million, up 11% year-over-year on a GAAP basis and up 10% year-over-year on a constant currency basis. Growth driven by 6.6% organic constant currency growth and contributions from acquisitions.
Non-GAAP Operating Margin (Q4 2025) 21%, an increase of 138 basis points year-over-year. Improvement attributed to product and geographic mix, as well as pricing improvements.
Non-GAAP EPS (Q4 2025) 12% growth year-over-year, exceeding expectations.
Free Cash Flow (Q4 2025) $74 million, up 13% year-over-year, marking a quarterly record for the company.
Total Revenue (Full Year 2025) 11% constant currency growth year-over-year, driven by 7% organic growth and $62 million from acquisitions.
Non-GAAP Operating Margin (Full Year 2025) 20.3%, a 131 basis point increase year-over-year. Improvement attributed to strong execution and commitment to financial targets.
Free Cash Flow (Full Year 2025) $215 million, up 16% year-over-year, driven by increased non-GAAP net income and improved working capital usage.
Cardiovascular Segment Revenue (Q4 2025) 9% growth year-over-year, driven by strong sales in Cardiac Intervention and Peripheral Intervention products.
Endoscopy Segment Revenue (Q4 2025) 15% growth year-over-year, meeting expectations.
Gross Margin (Q4 2025) 54.5%, up 103 basis points year-over-year, the highest quarterly gross margin in the company's history. Improvement driven by product and geographic mix and pricing improvements, offset by tariff headwinds.
Operating Income (Q4 2025) $82.7 million, up 19% year-over-year, with an operating margin of 21%.
Net Income (Q4 2025) $62.5 million, or $1.04 per share, compared to $56.3 million, or $0.93 per share, in the prior year period.
OEM Products Revenue (Q4 2025) Decreased 15% year-over-year, attributed to demand trends impacted by macro environment and customer inventory destocking.
U.S. Sales (Q4 2025) Increased 12% year-over-year, with 8% organic constant currency growth.
International Sales (Q4 2025) Increased 6% year-over-year, with 4% organic constant currency growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Contribution: Approximately 10% of the 2025 revenue growth in the two largest product categories, cardiac intervention and peripheral intervention, came from new products introduced in 2025.
Product Innovation: Merit has a consistent track record of developing and introducing new products that contribute significantly to annual growth.
Geographic Revenue Growth: U.S. sales increased 12% year-over-year, while international sales increased 6% year-over-year in Q4 2025.
Market Diversification: Roughly 40% of Merit’s revenue comes from customers outside the United States, showcasing a globally diversified revenue base.
Operational Efficiency: Non-GAAP operating margin increased to 21% in Q4 2025, up 138 basis points year-over-year, driven by product mix, geography, and pricing improvements.
Free Cash Flow: Generated $74 million in free cash flow in Q4 2025, a 13% year-over-year increase, and $216 million for the full year, up 16% year-over-year.
Strategic Divestiture: Divested the DualCap product line for $28 million in February 2026 to focus on higher-margin, higher-growth products.
Leadership Transition: New CEO Martha Aronson implemented changes including a new executive leadership team and global operating committee to enhance the company’s foundation for success.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs and Trade Policies: The company faces a significant impact from tariffs and trade policies, with an estimated $15 million or $0.19 per share impact in 2026, compared to $9 million or $0.12 per share in 2025. This represents a material headwind to profitability.
OEM Business Performance: The OEM segment experienced a 15% decline in sales during Q4 2025, attributed to customer inventory destocking and macroeconomic challenges, particularly outside the U.S. This underperformance could affect overall revenue growth.
Divestiture of DualCap Product Line: The divestiture of the DualCap product line, which contributed $20 million in 2025, will create a 140 basis point headwind to constant currency revenue growth in 2026. This could impact revenue and operational focus in the short term.
Macroeconomic Environment: The company continues to face challenges from a dynamic and uncertain global macroeconomic environment, which has impacted demand trends, particularly in the OEM segment.
Incremental Dilution from Convertible Debt: The company expects incremental dilution of approximately $0.01 per share in 2026 due to its convertible debt facility, which could slightly impact earnings per share.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Financial Guidance: Total GAAP net revenue growth projected in the range of 6% to 8% year-over-year and 5% to 7% year-over-year on a constant currency basis. Non-GAAP diluted earnings per share expected in the range of $4.01 to $4.15, up 5% to 8% year-over-year. Non-GAAP operating margins anticipated to expand by 36 to 76 basis points year-over-year, reaching approximately 20.6% to 21%. Free cash flow generation projected to be at least $200 million, inclusive of $90 million in capital expenditures.
Revenue Growth Drivers: U.S. revenue growth expected at 6% to 7%, and international revenue growth at 5% to 6%. Inorganic revenue contributions from acquisitions projected at $13 million to $15 million. Organic constant currency revenue growth anticipated in the range of 4.5% to 6% year-over-year.
Product and Portfolio Adjustments: Divestiture of the DualCap product line, representing a $20 million revenue headwind in 2026, to focus on higher-margin, higher-growth products. Incremental revenue from Rhapsody CIE expected to grow from $3 million in 2025 to $7 million in 2026.
First Quarter 2026 Guidance: Total revenue projected in the range of $375 million to $380 million, representing 6% to 7% year-over-year growth on a GAAP basis and 3% to 5% on a constant currency basis. Non-GAAP operating margins expected between 16.7% and 18.5%. Non-GAAP EPS projected in the range of $0.77 to $0.87.
Strategic Focus for 2026: Continued execution of growth initiatives targeting a 3-year organic constant currency revenue CAGR of 5% to 7%, non-GAAP operating margin of 20% to 22%, and cumulative free cash flow generation of more than $400 million by the end of 2026. Development of a strategic plan for 2027-2030, focusing on foundational and therapeutic product platforms, disciplined M&A, and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the additional gross margin drivers for the company?
A:The company continues to focus on mix, including new R&D projects, acquisitions, SKU rationalization, pricing, cost discipline, and moving production to lower-cost areas. The divestiture of low-margin products like DualCap also contributes to gross margin improvement.
Q:Is the Rhapsody business performing as expected?
A:The company acknowledges that their original 2025 Rhapsody revenue expectations missed the mark. They have set a $7 million revenue expectation for 2026, which they are confident in achieving. The product is seen as high-performing and supported by clinical data, but the market is competitive.
Q:Why is the 2026 free cash flow guidance lower than 2025?
A:The 2026 free cash flow guidance of $200 million is a minimum target. The lower guidance is attributed to timing-based items, increased CapEx spend, and conservatism due to unpredictable factors. The company remains focused on achieving its CGI goals.
Q:What areas is the company targeting for M&A?
A:The company is focusing on both foundational and therapeutic products that align with their platforms. They are looking for opportunities to fill gaps in their sales reps' portfolios and enhance growth drivers in areas like EP, dialysis, and endoscopy.
Q:What caused the inventory destocking in OEM during Q4?
A:In the U.S., the inventory destocking was customer-driven, while outside the U.S., it was due to macroeconomic factors, particularly in China. The company expects normalized growth in OEM to be in the mid- to high single digits.
Q:Why is the Q1 2026 organic growth guidance only 2%-3%?
A:The lower Q1 growth is due to the divestiture of DualCap, continued OEM softness, macroeconomic challenges in China, and supply chain-related issues. The company expects these issues to resolve as the year progresses.
Q:What is the long-term vision for Rhapsody?
A:The company views Rhapsody as a platform rather than a one-off product. They are conducting strategic planning to identify future opportunities and believe the product has significant market potential. They are not ready to share specific long-term targets.
Q:What is the contribution of Rhapsody to 2026 growth?
A:Rhapsody is expected to contribute approximately 25 basis points to the company's constant currency growth range for 2026. The product is in the early stages of commercialization under a new strategy.
Q:What drove the growth in the SCOUT system?
A:The SCOUT system and related delivery systems grew by more than 25% year-over-year, contributing nearly 45% of the total PI growth. The growth is attributed to strong sales efforts, clinical value, and overcoming previous supply chain issues.
Q:What were the regional performances in Q4?
A:U.S. sales increased by 12% year-over-year (8% organic constant currency). International sales grew by 6% year-over-year (4% organic constant currency). APAC grew by 3%, EMEA by 12%, and the rest of the world by 4.5% on a constant currency basis.
Q:What is the company's approach to R&D and PMA products?
A:The company plans to continue pursuing PMA products and leveraging their technical talent. They are focusing on strategic planning to identify opportunities that align with their platforms and customer needs.
Q:What is the company's capital allocation strategy?
A:The company is open to slightly larger acquisitions than in the past, focusing on tuck-ins or slightly larger deals that align with their growth strategy. They aim to remain disciplined and strategic in their approach.
Q:Review of Unclear Management Responses
A:Management avoided providing specific long-term growth targets for Rhapsody and did not detail the margin contribution of the product. They also did not provide a detailed breakdown of the Q1 2026 margin considerations beyond general factors like tariffs and expense base.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America sale
BioLife acquisition
CI sale
CIE decision
CPS divestiture
Custom Procedural
EP CRM
OEM sale
PI sale
Prelude
Procedural Solutions
SNAP
Supreme Court
access product
angiography access
closing
commitment
contribution acquisition
contributor
currency contribution
currency margin
currency non
environment
expectation review
flow increase
harbor
improvement margin
line product
margin expansion
month tariff
non margin
obligation borrowing
product end
release currency
result end
sale result
tariff policy
teen
MMSI Transcript
Merit Medical Systems, Inc. (MMSI) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call reveals solid financial performance with record-high gross margins, strong operating income growth, and positive revenue projections, especially in the cardiovascular and endoscopy segments. Despite some concerns over OEM revenue and cautious Q1 2026 guidance, the company's strategic acquisitions and optimistic long-term outlook for Rhapsody and other products support a positive sentiment. The market cap suggests a moderate reaction, leading to a 2%-8% stock price increase prediction.
Merit Medical Systems, Inc. (MMSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Merit Medical Systems, Inc. (MMSI) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call summary reflects a positive outlook with strong financial metrics, optimistic guidance, and strategic focus on growth. The Q&A section confirmed strong free cash flow and potential for acquisitions, while addressing concerns about expenses and market dynamics. The company's clear strategy for growth, including WRAPSODY and CryoBalloon C2, supports a positive sentiment. Given the market cap, the stock price is likely to react positively, within the 2% to 8% range, over the next two weeks.
Merit Medical Systems, Inc. (MMSI) Q2 2025 Earnings Call Transcript
Positive7-31
The earnings call highlights strong financial performance with record operating margins and revenue growth, particularly in cardiac interventions. Despite a decline in China sales and tariff impacts, the company has raised its operating margin guidance and expects sustainable growth in key areas. While there are uncertainties, such as the WRAPSODY filing delay, management's confidence in overcoming these challenges and their strategic focus on acquisitions and market expansion suggest a positive outlook. Given the company's market cap and the positive sentiment, a stock price increase of 2% to 8% is likely.
MMSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
